2. Academic Validation
  3. Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes

Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes

  • ACS Med Chem Lett. 2011 Sep 13;2(11):824-7. doi: 10.1021/ml2001467.
Aiwen Li 1,  Chester C Yuan 1,  David Chow 1,  Michelle Chen 1,  Maurice G Emery 1,  Clarence Hale 1,  Xiping Zhang 1,  Raju Subramanian 1,  David J St Jean Jr 1,  Renee Komorowski 1,  Murielle Véniant 1,  Minghan Wang 1,  Christopher Fotsch 1
Affiliations

Affiliation

  • 1 Departments of Chemistry Research and Discovery, Metabolic Disorders, and Pharmacokinetics and Drug Metabolism, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.
PMID: 24900270 DOI: 10.1021/ml2001467
Abstract

All eight of the major active metabolites of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221, compound 1), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 that has entered the clinic for the treatment of type 2 diabetes, were synthetically prepared and confirmed by comparison with samples generated in liver microsomes. After further profiling, we determined that metabolite 2 was equipotent to 1 on human 11β-HSD1 and had lower in vivo clearance and higher bioavailability in rat and mouse. Compound 2 was advanced into a pharmacodynamic model in mouse where it inhibited adipose 11β-HSD1 activity.

Keywords

11β-HSD1 inhibitors; AMG 221; clinical candidate; metabolites.

Figures
Products